AUS
NZ
UK
CA
USA
IND
Highlights:
Abbott is projected to report Q3 2024 revenue of $10.6 billion and adjusted earnings of $1.20 per share, aligning with market expectations.
Growth is anticipated across multiple segments, particularly driven by increased sales of the FreeStyle Libre glucose monitoring system.
The company may experience a slight rise in pre-tax margins, contributing positively to overall profitability.
Abbott Laboratories (NYSE:ABT) is set to announce its Q3 2024 financial results on October 16, 2024. Analysts project the company will generate approximately $10.6 billion in revenue and adjusted earnings of $1.20 per share. This performance aligns with overall market expectations and reflects a mid-single-digit growth rate, largely attributed to higher sales of the FreeStyle Libre diabetes monitoring products.
The company is expected to show steady growth across its various segments. The Nutrition segment is likely to benefit from market share gains in baby formula products, while the Medical Devices division is poised for increased sales driven by a rise in procedure volume and ongoing demand for diabetes-related products. Notably, the FreeStyle Libre product line is anticipated to continue its growth trajectory following the recent U.S. FDA clearance of Abbott's new over-the-counter glucose monitoring devices, Libre Rio and Lingo. This development is expected to bolster overall sales in the diabetes portfolio.
In Q2 2024, Abbott reported revenue of $10.4 billion, representing a year-over-year increase of 4%. The Medical Devices segment saw an impressive sales increase of 10.2%, while the Nutrition segment grew by 3.5%. However, the Diagnostics division faced challenges due to decreased demand for COVID-19 testing, resulting in a 5.3% decline in revenues. Excluding COVID-19 tests, Diagnostic sales rose by 5.9%. Abbott’s adjusted pre-tax income margin expanded to 22.7% in Q2, contributing to a 5.6% rise in adjusted earnings.
Currently, Abbott's stock is deemed fairly valued at around $116 per share, with a projected valuation of $119 based on a price-to-earnings ratio of 25, aligning with the company’s historical averages. With Q3 performance expected to be in line with projections, stock movement may remain stable. Investors should monitor pre-tax margins, potential revisions in earnings forecasts, and demand trends for diabetes products, which may influence short-term stock performance.
